Drugs / LAD328
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07547813 | Apr 2026 → Feb 2027 expected | hidradenitis suppurativa | Almirall, S.A. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAD328 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07547813 ↗ |
| Route | Intravenous | “LAD328 administered intravenously.” NCT07547813 ↗ |